Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.

Peiting ZengWenhua LuJingyu TianShuang QiaoJiangjiang LiChristophe GlorieuxShijun WenHui ZhangYiqing LiPeng Huang

Published in: Journal of hematology & oncology (2022)

Wt-IDH2 is an essential molecule for AML cell survival and proliferation by promoting conversion of α-KG to isocitrate for lipid synthesis and by upregulating c-Myc expression and could be a potential therapeutic target in AML.

Keyphrases

wild type
acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
poor prognosis
climate change
low grade
signaling pathway
fatty acid
long non coding rna
risk assessment